Market capitalization | $1.67b |
Enterprise Value | $440.37m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.72 |
P/S ratio (TTM) P/S ratio | 17.92 |
P/B ratio (TTM) P/B ratio | 2.78 |
Revenue growth (TTM) Revenue growth | -39.92% |
Revenue (TTM) Revenue | $93.30m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
18 Analysts have issued a Arvinas, Inc. forecast:
18 Analysts have issued a Arvinas, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 93 93 |
40%
40%
|
|
Gross Profit | 87 87 |
41%
41%
|
|
EBITDA | -364 -364 |
22%
22%
|
EBIT (Operating Income) EBIT | -371 -371 |
22%
22%
|
Net Profit | -323 -323 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
Head office | United States |
CEO | John Houston |
Employees | 445 |
Founded | 2013 |
Website | www.arvinas.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.